Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2016 (2016), Article ID 4385643, 34 pages
http://dx.doi.org/10.1155/2016/4385643
Special Article

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment

1British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, Canada V6T 1Z4
2University of Alberta, Edmonton, AB, Canada T6G 2R3
3Regina Qu’Appelle Health Region, Regina, SK, Canada S4P 1E2
4Toronto General Hospital, Toronto, ON, Canada M5G 2C4
5The Ottawa Hospital, Ottawa, ON, Canada K1H 8L6
6Dalhousie University, Halifax, NS, Canada B3H 4R2
7McMaster University, Hamilton, ON, Canada L8S 4L8
8Vancouver Infectious Diseases Centre, Vancouver, BC, Canada V6Z 2C7
9McGill University, Montreal, QC, Canada H3A 0G4
10The Ottawa Hospital, General Campus, G12, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6

Received 25 September 2015; Accepted 15 December 2015

Copyright © 2016 Mark Hull et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Nakagawa, R. K. Lodwick, C. J. Smith et al., “Projected life expectancy of people with HIV according to timing of diagnosis,” AIDS, vol. 26, no. 3, pp. 335–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Samji, A. Cescon, R. S. Hogg et al., “Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada,” PLoS ONE, vol. 8, no. 12, Article ID e81355, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, J. W. Ward, and S. D. Holmberg, “The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007,” Annals of Internal Medicine, vol. 156, no. 4, pp. 271–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. B. Klein, K. C. Rollet, S. Saeed et al., “HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality,” HIV Medicine, vol. 14, no. 1, pp. 10–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Weber, C. A. Sabin, N. Friis-Moller et al., “Liver-related deaths in persons infected with the human immunodeficiency virus the D:A:D study,” Archives of Internal Medicine, vol. 166, no. 15, pp. 1632–1641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. S. Coffin, S. K. Fung, and M. M. Ma, “Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines,” Canadian Journal of Gastroenterology, vol. 26, no. 12, pp. 917–938, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Myers, A. Ramji, M. Bilodeau, S. Wong, and J. J. Feld, “An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver,” Canadian Journal of Gastroenterology, vol. 26, no. 6, pp. 359–375, 2012. View at Google Scholar
  8. V. D. Lima, R. S. Hogg, P. R. Harrigan et al., “Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy,” AIDS, vol. 21, no. 6, pp. 685–692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. S. Hogg, B. Yip, C. Kully et al., “Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens,” CMAJ, vol. 160, no. 5, pp. 659–665, 1999. View at Google Scholar · View at Scopus
  10. D. L. Thomas, “The challenge of hepatitis C in the HIV-infected person,” Annual Review of Medicine, vol. 59, pp. 473–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. World Health Organization, Hepatitis C, World Health Organization, Geneva, Switzerland, 2002, http://www.who.int/csr/disease/hepatitis/Hepc.pdf.
  12. C. W. Shepard, L. Finelli, and M. J. Alter, “Global epidemiology of hepatitis C virus infection,” The Lancet Infectious Diseases, vol. 5, no. 9, pp. 558–567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Trubnikov, P. Yan, and C. Archibald, “Estimated prevalence of Hepatitis C Virus infection in Canada, 2011,” Canada Communicable Disease Report, vol. 40-19, pp. 429–436, 2014. View at Google Scholar
  14. R. S. Remis, Modelling the Incidence and Prevalence of Hepatitis C Infection and its Sequelae in Canada, 2007, Community Acquired Infections Division, Public Health Agency of Canada, Ottawa, Canada, 2007.
  15. Public Health Agency of Canada, HIV/AIDS Epi Updates: National HIV Prevalence and Incidence Estimates for 2011, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2014.
  16. R. Parent, M. Alary, C. Morissette, E. Roy, P. Leclerc, and P. R. Allard, Surveillance des Maladies Infectieuses Chez les Utilisateurs de Drogue par Injection: Épidémiologie du VIH de 1995 à 2008, Institut National de Santé Publique, 2009, http://www.inspq.qc.ca/pdf/publications/1021_SurvMalInfecUDI_VIHVHC2008.pdf.
  17. A. Frescura, L. Fang, M. Trubnikov, S. Klar, and G. Jayaraman, Hepatitis C in Canada: 2005–2010 Surveillance Report, Edited by Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Canada, 2011.
  18. S. F. O'Brien, Q.-L. Yi, W. Fan, V. Scalia, S. H. Kleinman, and E. C. Vamvakas, “Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services,” Transfusion, vol. 47, no. 2, pp. 316–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. L. Wylie, L. Shah, and A. M. Jolly, “Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada,” BMC Public Health, vol. 6, article 229, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C. S. Bradshaw, L. I. Pierce, S. N. Tabrizi, C. K. Fairley, and S. M. Garland, “Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sampling,” Sexually Transmitted Infections, vol. 81, no. 1, pp. 53–58, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. Viral Hepatitis—Statistics & Surveillance, Viral Hepatitis Surveillance—United States, 2010, Centers for Disease Control and Prevention (CDC), Atlanta, Ga, USA, 2010, http://www.cdc.gov/hepatitis/statistics/2010surveillance/index.htm.
  22. Public Health Agency of Canada, Epi-Update: Hepatitis C Virus Infection in Canadian Street Youth (1999–2005), Community Acquired Infections Division, 2008.
  23. Public Health Agency of Canada, Hepatitis C in Canada: 2005–2010 Surveillance Report, Edited by Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada, Ottawa, Canada, 2011.
  24. Saskatchewan Ministry of Health, Saskatchewan HIV Strategy 2012, 2012, http://www.health.gov.sk.ca/HIV-strategy-update.
  25. M. B. Klein, S. Saeed, H. Yang et al., “Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study,” International Journal of Epidemiology, vol. 39, no. 5, pp. 1162–1169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Calzavara, N. Ramuscak, A. N. Burchell et al., “Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities,” CMAJ, vol. 177, no. 3, pp. 257–261, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Zakaria, J. M. Thompson, A. Jarvis, and F. Borgatta, Summary of Emerging Findings from the 2007 National Inmate Infectious Diseases and Risk-Behaviours Survey, Correctional Service Canada, 2010.
  28. C. L. Miller, C. Johnston, P. M. Spittal et al., “Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users,” Hepatology, vol. 36, no. 3, pp. 737–742, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. P. M. Spittal, M. E. Pearce, N. Chavoshi et al., “The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities,” BMC Public Health, vol. 12, no. 1, article 632, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. C. L. C. Collins, T. Kerr, M. W. Tyndall et al., “Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users,” Canadian Journal of Public Health, vol. 96, no. 5, pp. 344–347, 2005. View at Google Scholar · View at Scopus
  31. T. Kerr, J.-A. Stoltz, M. Tyndall et al., “Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study,” British Medical Journal, vol. 332, no. 7535, pp. 220–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Wood, T. Kerr, J. S. Montaner et al., “Rationale for evaluating North America's first medically supervised safer-injecting facility,” Lancet Infectious Diseases, vol. 4, no. 5, pp. 301–306, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Wood, T. Kerr, P. M. Spittal et al., “The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users,” Journal of Acquired Immune Deficiency Syndromes, vol. 32, no. 1, pp. 2–8, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. N. K. Martin, M. Hickman, S. J. Hutchinson, D. J. Goldberg, and P. Vickerman, “Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy,” Clinical Infectious Diseases, vol. 57, supplement 2, pp. S39–S45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. J. G. Clarke, M. D. Stein, L. Hanna, M. Sobota, and J. D. Rich, “Active and former injection drug users report of HIV risk behaviors during periods of incarceration,” Substance Abuse, vol. 22, no. 4, pp. 209–216, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. M.-J. Milloy, E. Wood, W. Small et al., “Incarceration experiences in a cohort of active injection drug users,” Drug and Alcohol Review, vol. 27, no. 6, pp. 693–699, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. M. Orsi and S. Brochu, “The place of needle-exchange programs among harm reduction strategies in Canadian prisons,” Canadian Journal of Public Health, vol. 100, no. 1, pp. 29–31, 2009. View at Google Scholar · View at Scopus
  38. J. A. Buxton, A. Yu, P. H. Kim et al., “HCV co-infection in HIV positive population in British Columbia, Canada,” BMC Public Health, vol. 10, article 225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. N. A. Terrault, J. L. Dodge, E. L. Murphy et al., “Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study,” Hepatology, vol. 57, no. 3, pp. 881–889, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Danta and G. M. Dusheiko, “Acute HCV in HIV-positive individuals—a review,” Current Pharmaceutical Design, vol. 14, no. 17, pp. 1690–1697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. A. T. Urbanus, T. J. van de Laar, I. G. Stolte et al., “Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic,” AIDS, vol. 23, no. 12, pp. F1–F7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Vogel and J. K. Rockstroh, “Treatment of acute hepatitis C in HIV infection,” The Journal of antimicrobial chemotherapy, vol. 65, no. 1, pp. 4–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. T. L. Wright, H. Hollander, X. Pu et al., “Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival,” Hepatology, vol. 20, no. 5, pp. 1152–1155, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Yaphe, N. Bozinoff, R. Kyle, S. Shivkumar, N. P. Pai, and M. Klein, “Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review,” Sexually Transmitted Infections, vol. 88, no. 7, pp. 558–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Richardson, M. Fisher, and C. A. Sabin, “Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection,” Journal of Infectious Diseases, vol. 197, no. 8, pp. 1213–1214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Jin, G. P. Prestage, G. Matthews et al., “Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia,” Sexually Transmitted Infections, vol. 86, no. 1, pp. 25–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. T. J. W. van de Laar, A. K. van der Bij, M. Prins et al., “Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission,” Journal of Infectious Diseases, vol. 196, no. 2, pp. 230–238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Daskalopoulou, A. Rodger, A. Thornton et al., “Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study,” Journal of the International AIDS Society, vol. 17, supplement 3, no. 4, Article ID 19630, 2014. View at Publisher · View at Google Scholar
  49. G. V. Matthews, S. T. Pham, M. Hellard et al., “Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C,” Clinical Infectious Diseases, vol. 52, no. 6, pp. 803–811, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel, “Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference,” Aids, vol. 25, no. 4, pp. 399–409, 2011. View at Publisher · View at Google Scholar
  51. B. P. Linas, A. Y. Wong, B. R. Schackman, A. Y. Kim, and K. A. Freedberg, “Cost-effective screening for acute hepatitis C virus infection in hiv-infected men who have sex with men,” Clinical Infectious Diseases, vol. 55, no. 2, pp. 279–290, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. J. de Bruijne, J. Schinkel, M. Prins et al., “Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles,” Journal of Clinical Microbiology, vol. 47, no. 12, pp. 3832–3838, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Andonov and R. K. Chaudhary, “Genotyping of Canadian hepatitis C virus isolates by PCR,” Journal of Clinical Microbiology, vol. 32, no. 8, pp. 2031–2034, 1994. View at Google Scholar · View at Scopus
  54. N. A. Antonishyn, V. M. Ast, R. R. McDonald et al., “Rapid genotyping of hepatitis C virus by primer-specific extension analysis,” Journal of Clinical Microbiology, vol. 43, no. 10, pp. 5158–5163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Poynard, V. Ratziu, F. Charlotte, Z. Goodman, J. McHutchison, and J. Albrecht, “Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C,” Journal of Hepatology, vol. 34, no. 5, pp. 730–739, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. V. Di Martino, J. Crouzet, P. Hillon, T. Thévenot, A. Minello, and E. Monnet, “Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis,” Journal of Viral Hepatitis, vol. 18, no. 7, pp. 493–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. T. E. Wiley, J. Brown, and J. Chan, “Hepatitis C infection in African Americans: its natural history and histological progression,” The American Journal of Gastroenterology, vol. 97, no. 3, pp. 700–706, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Wiese, K. Grüngreiff, W. Güthoff et al., “Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study,” Journal of Hepatology, vol. 43, no. 4, pp. 590–598, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Ferenci, S. Ferenci, C. Datz, I. Rezman, W. Oberaigner, and R. Strauss, “Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s,” Journal of Hepatology, vol. 47, no. 1, pp. 31–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. S. Sulkowski, “Viral hepatitis and HIV coinfection,” Journal of Hepatology, vol. 48, no. 2, pp. 353–367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. E. C. Seaberg, M. D. Witt, L. P. Jacobson et al., “Spontaneous clearance of the hepatitis C virus among men who have sex with men,” Clinical Infectious Diseases, vol. 61, no. 9, pp. 1381–1388, 2015. View at Google Scholar
  62. V. Soriano, A. Mocroft, J. Rockstroh et al., “Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe,” Journal of Infectious Diseases, vol. 198, no. 9, pp. 1337–1344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. G. D. Kirk, S. H. Mehta, J. Astemborski et al., “HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study,” Annals of Internal Medicine, vol. 158, no. 9, pp. 658–667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. H. K. Monga, M. C. Rodriguez-Barradas, K. Breaux et al., “Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection,” Clinical Infectious Diseases, vol. 33, no. 2, pp. 240–247, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Berenguer, E. Rodríguez, P. Miralles et al., “Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus,” Clinical Infectious Diseases, vol. 55, no. 5, pp. 728–736, 2012. View at Publisher · View at Google Scholar
  66. M. A. Konerman, S. H. Mehta, C. G. Sutcliffe et al., “Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs,” Hepatology, vol. 59, no. 3, pp. 767–775, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Benhamou, M. Bochet, V. Di Martino et al., “Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients,” Hepatology, vol. 30, no. 4, pp. 1054–1058, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Martinez-Sierra, A. Arizcorreta, F. Diaz et al., “Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus,” Clinical Infectious Diseases, vol. 36, no. 4, pp. 491–498, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. M. S. Sulkowski, S. H. Mehta, M. S. Torbenson et al., “Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults,” AIDS, vol. 21, no. 16, pp. 2209–2216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. B. N. Limketkai, S. H. Mehta, C. G. Sutcliffe et al., “Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV,” The Journal of the American Medical Association, vol. 308, no. 4, pp. 370–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Grint, L. Peters, J. K. Rockstroh et al., “Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals,” AIDS, vol. 29, no. 10, pp. 1205–1215, 2015. View at Publisher · View at Google Scholar
  72. E. Rosenthal, D. Salmon-Céron, C. Lewden et al., “Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19),” HIV Medicine, vol. 10, no. 5, pp. 282–289, 2009. View at Publisher · View at Google Scholar
  73. N. Bräu, R. K. Fox, P. Xiao et al., “Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study,” Journal of Hepatology, vol. 47, no. 4, pp. 527–537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Merchante, E. Merino, J. López-Aldeguer et al., “Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain,” Clinical Infectious Diseases, vol. 56, no. 1, pp. 143–150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. J. C. Kwong, N. S. Crowcroft, M. A. Campitelli et al., Ontario Burden of Infectious Disease Study (ONBOIDS): An OAHPP/ICES Report, Ontario Agency for Health Protection and Promotion, Institute for Clinical Evaluative Sciences, Toronto, Canada, 2010.
  76. R. P. Myers, M. Krajden, M. Bilodeau et al., “Burden of disease and cost of chronic hepatitis C virus infection in Canada,” Canadian Journal of Gastroenterology and Hepatology, vol. 28, no. 5, pp. 243–250, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. C. S. Graham, L. R. Baden, E. Yu et al., “Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis,” Clinical Infectious Diseases, vol. 33, no. 4, pp. 562–569, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Soto, A. Sánchez-Quijano, L. Rodrigo et al., “Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis,” Journal of Hepatology, vol. 26, no. 1, pp. 1–5, 1997. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Bräu, M. Salvatore, C. F. Ríos-Bedoya et al., “Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy,” Journal of Hepatology, vol. 44, no. 1, pp. 47–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Tural, D. Fuster, J. Tor et al., “Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients,” Journal of Viral Hepatitis, vol. 10, no. 2, pp. 118–125, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Qurishi, C. Kreuzberg, G. Lüchters et al., “Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection,” The Lancet, vol. 362, no. 9397, pp. 1708–1713, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Bonacini, S. Louie, N. Bzowej, and A. R. Wohl, “Survival in patients with HIV infection and viral hepatitis B or C: a cohort study,” AIDS, vol. 18, no. 15, pp. 2039–2045, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. J. P. Anderson, E. J. Tchetgen Tchetgen, V. Lo Re et al., “Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus–coinfected veterans,” Clinical Infectious Diseases, vol. 58, no. 5, pp. 719–727, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. S. D. Shafran, “Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 44, no. 5, pp. 551–556, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. V. L. Re III, M. J. Kallan, J. P. Tate et al., “Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study,” Annals of Internal Medicine, vol. 160, no. 6, pp. 369–379, 2014. View at Google Scholar · View at Scopus
  86. H. F. Günthard, J. A. Aberg, J. J. Eron et al., “Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel,” The Journal of the American Medical Association, vol. 312, no. 4, pp. 410–425, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. Panel on Antiretroviral Guidelines for Adults and Adolescents, “Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,” Department of Health and Human Services, August 2015, http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
  88. I. Williams, D. Churchill, J. Anderson et al., “British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012,” HIV Medicine, vol. 13, supplement 2, pp. 1–6, 2012. View at Publisher · View at Google Scholar
  89. N. Clumeck, A. d'Arminio Monforte, and J. R. Arribas, “European AIDS Clinical Society. Guidelines: Clinical Management and Treatment of HIV-infected adults in Europe. Version 7.1,” November 2014, http://www.eacsociety.org/files/guidelines_english_71_141204.pdf.
  90. P. Labarga, V. Soriano, M. E. Vispo et al., “Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients,” Journal of Infectious Diseases, vol. 196, no. 5, pp. 670–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. M. S. Sulkowski, D. L. Thomas, R. E. Chaisson, and R. D. Moore, “Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection,” Journal of the American Medical Association, vol. 283, no. 1, pp. 74–80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Núñez, “Hepatotoxicity of antiretrovirals: incidence, mechanisms and management,” Journal of Hepatology, vol. 44, no. 1, supplement, pp. S132–S139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Aceti, C. Pasquazzi, B. Zechini et al., “Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 1, pp. 41–48, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Núñez, R. Lana, J. L. Mendoza, L. Martín-Carbonero, and V. Soriano, “Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 27, no. 5, pp. 426–431, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. J. C. Servoss, D. W. Kitch, J. W. Andersen, R. B. Reisler, R. T. Chung, and G. K. Robbins, “Predictors of antiretroviral-related hepatotoxicity in the Adult AIDS Clinical Trial Group (1989–1999),” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 3, pp. 320–323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. F. W. N. M. Wit, G. J. Weverling, J. Weel, S. Jurriaans, and J. M. A. Lange, “Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy,” Journal of Infectious Diseases, vol. 186, no. 1, pp. 23–31, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. M. den Brinker, F. W. N. M. Wit, P. M. E. Wertheim-van Dillen et al., “Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection,” AIDS, vol. 14, no. 18, pp. 2895–2902, 2000. View at Publisher · View at Google Scholar · View at Scopus
  98. M. S. Sulkowski, D. L. Thomas, S. H. Mehta, R. E. Chaisson, and R. D. Moore, “Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections,” Hepatology, vol. 35, no. 1, pp. 182–189, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. J. K. Rockstroh, H. Teppler, J. Zhao et al., “Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection,” HIV Medicine, vol. 13, no. 2, pp. 127–131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. S. L. Walmsley, A. Antela, N. Clumeck et al., “Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection,” The New England Journal of Medicine, vol. 369, no. 19, pp. 1807–1818, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Nelson, G. Amaya, N. Clumeck et al., “Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 8, pp. 2020–2028, 2012. View at Publisher · View at Google Scholar
  102. B. Clotet, N. Clumeck, C. Katlama, S. Nijs, and J. Witek, “Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the phase III DUET trials,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 11, pp. 2450–2454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Rachlis, B. Clotet, J. Baxter, R. Murphy, and E. Lefebvre, “Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3,” HIV Clinical Trials, vol. 8, no. 4, pp. 213–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. E. DeJesus, J. K. Rockstroh, K. Henry et al., “Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial,” The Lancet, vol. 379, no. 9835, pp. 2429–2438, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. P. E. Sax, E. DeJesus, A. Mills et al., “Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks,” The Lancet, vol. 379, no. 9835, pp. 2439–2448, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Aranzabal, J. L. Casado, J. Moya et al., “Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection,” Clinical Infectious Diseases, vol. 40, no. 4, pp. 588–593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Macías, V. Castellano, N. Merchante et al., “Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine,” AIDS, vol. 18, no. 5, pp. 767–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. E. E. M. Moodie, N. P. Pai, and M. B. Klein, “Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts,” PLoS ONE, vol. 4, no. 2, Article ID e4517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Núñez, P. Ríos, L. Martín-Carbonero, M. Pérez-Olmeda, J. González-Lahoz, and V. Soriano, “Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 30, no. 1, pp. 65–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Torti, G. Lapadula, M. Puoti et al., “Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER cohort,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 2, pp. 180–185, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Beld, M. Penning, M. van Putten et al., “Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody- undetectable periods before seroconversion,” Blood, vol. 94, no. 4, pp. 1183–1191, 1999. View at Google Scholar · View at Scopus
  112. D. Brown, L. Powell, A. Morris et al., “Improved diagnosis of chronic hepatitis C virus infection by detection of antibody to multiple epitopes: confirmation by antibody to synthetic oligopeptides,” Journal of Medical Virology, vol. 38, no. 3, pp. 167–171, 1992. View at Publisher · View at Google Scholar · View at Scopus
  113. M. W. Hull, K. Rollet, A. Odueyungbo et al., “Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus,” Clinical Infectious Diseases, vol. 54, no. 12, pp. 1798–1805, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. C. W. Claassen, M. Diener-West, S. H. Mehta, D. L. Thomas, and G. D. Kirk, “Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis,” Clinical Infectious Diseases, vol. 54, no. 12, pp. 1806–1813, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Castéra, J. Vergniol, J. Foucher et al., “Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C,” Gastroenterology, vol. 128, no. 2, pp. 343–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Castera, M. Winnock, E. Pambrun et al., “Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration,” HIV Medicine, vol. 15, no. 1, pp. 30–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Uberti-Foppa, A. De Bona, L. Galli et al., “Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 1, pp. 63–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. D. E. Kleiner, “The liver biopsy in chronic hepatitis C: a view from the other side of the microscope,” Seminars in Liver Disease, vol. 25, no. 1, pp. 52–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Regev, M. Berho, L. J. Jeffers et al., “Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection,” The American Journal of Gastroenterology, vol. 97, no. 10, pp. 2614–2618, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. V. De Lédinghen and J. Vergniol, “Transient elastography for the diagnosis of liver fibrosis,” Expert Review of Medical Devices, vol. 7, no. 6, pp. 811–823, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Ziol, A. Handra-Luca, A. Kettaneh et al., “Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C,” Hepatology, vol. 41, no. 1, pp. 48–54, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Friedrich-Rust, M.-F. Ong, S. Martens et al., “Performance of transient elastography for the staging of liver fibrosis: a meta-analysis,” Gastroenterology, vol. 134, no. 4, pp. 960.e8–974.e8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Stebbing, L. Farouk, G. Panos et al., “A Meta-analysis of transient elastography for the detection of hepatic fibrosis,” Journal of Clinical Gastroenterology, vol. 44, no. 3, pp. 214–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Vergara, J. Macías, A. Rivero et al., “The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection,” Clinical Infectious Diseases, vol. 45, no. 8, pp. 969–974, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. G. D. Kirk, J. Astemborski, S. H. Mehta et al., “Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-Hepatitis C virus coinfection,” Clinical Infectious Diseases, vol. 48, no. 7, pp. 963–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. V. de Ledinghen, J. Vergniol, J. Foucher, F. El-Hajbi, W. Merrouche, and V. Rigalleau, “Feasibility of liver transient elastography with FibroScan using a new probe for obese patients,” Liver International, vol. 30, no. 7, pp. 1043–1048, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Al-Mohri, C. Cooper, T. Murphy, and M. B. Klein, “Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients,” HIV Medicine, vol. 6, no. 6, pp. 375–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  129. H. Al-Mohri, T. Murphy, Y. Lu, R. G. Lalonde, and M. B. Klein, “Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker,” Journal of Acquired Immune Deficiency Syndromes, vol. 44, no. 4, pp. 463–469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. R. K. Sterling, E. Lissen, N. Clumeck et al., “Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection,” Hepatology, vol. 43, no. 6, pp. 1317–1325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. T. Poynard, R. Morra, P. Halfon et al., “Meta-analyses of FibroTest diagnostic value in chronic liver disease,” BMC Gastroenterology, vol. 7, article 40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. A. A. M. Shaheen and R. P. Myers, “Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection,” HIV Clinical Trials, vol. 9, no. 1, pp. 43–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. V. de Lédinghen, C. Douvin, A. Kettaneh et al., “Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 2, pp. 175–179, 2006. View at Publisher · View at Google Scholar · View at Scopus
  134. M. Sánchez-Conde, M. L. Montes-Ramírez, P. Miralles et al., “Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers,” Journal of Viral Hepatitis, vol. 17, no. 4, pp. 280–286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. R. J. Hilsden, G. Macphail, J. Grebely, B. Conway, and S. S. Lee, “Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial,” Clinical Infectious Diseases, vol. 57, no. 2, pp. S90–S96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. C. Okuse, H. Yotsuyanagi, Y. Nagase et al., “Risk factors for retinopathy associated with interferon α-2b ribavirin combination therapy in patients with chronic hepatitis C,” World Journal of Gastroenterology, vol. 12, no. 23, pp. 3756–3759, 2006. View at Google Scholar · View at Scopus
  137. A. B. Shahidullah, M. A. Cerulli, and D. H. Berman, “Interferon may cause retinopathy during hepatitis therapy,” American Journal of Gastroenterology, vol. 90, no. 9, p. 1543, 1995. View at Google Scholar · View at Scopus
  138. J. Grebely, B. Conway, J. D. Raffa, C. Lai, M. Krajden, and M. W. Tyndall, “Hepatitis C virus reinfection in injection drug users,” Hepatology, vol. 44, no. 5, pp. 1139–1145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. N. K. Martin, P. Vickerman, G. R. Foster, S. J. Hutchinson, D. J. Goldberg, and M. Hickman, “Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility,” Journal of Hepatology, vol. 54, no. 6, pp. 1137–1144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. J. G. McHutchison, M. Manns, K. Patel et al., “Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C,” Gastroenterology, vol. 123, no. 4, pp. 1061–1069, 2002. View at Publisher · View at Google Scholar · View at Scopus
  141. T. Mathes, S.-L. Antoine, and D. Pieper, “Factors influencing adherence in Hepatitis-C infected patients: a systematic review,” BMC Infectious Diseases, vol. 14, article 203, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. P. Marcellin, M. Chousterman, T. Fontanges et al., “Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study,” Liver International, vol. 31, no. 4, pp. 516–524, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Kohli, A. Osinusi, Z. Sims et al., “Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study,” The Lancet, vol. 385, no. 9973, pp. 1107–1113, 2015. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Grebely, E. Knight, K. A. Genoway et al., “Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support,” European Journal of Gastroenterology and Hepatology, vol. 22, no. 3, pp. 270–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. R. Milne, M. Price, B. Wallace et al., “From principles to practice: description of a novel equity-based HCV primary care treatment model for PWID,” International Journal of Drug Policy, vol. 26, no. 10, pp. 1020–1027, 2015. View at Publisher · View at Google Scholar · View at Scopus
  146. A. Rivero-Juárez, J. A. Mira, I. Pérez-Camacho et al., “Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 6, pp. 1351–1353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Berenguer, J. Álvarez-Pellicer, P. M. Martín et al., “Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus,” Hepatology, vol. 50, no. 2, pp. 407–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. J. Grebely, J. D. Raffa, C. Lai et al., “Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents,” Journal of Viral Hepatitis, vol. 16, no. 5, pp. 352–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. C. Vellozzi, K. Buchacz, R. Baker et al., “Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999–2007,” Journal of Viral Hepatitis, vol. 18, no. 5, pp. 316–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  150. F. Carrat, F. Bani-Sadr, S. Pol et al., “Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial,” The Journal of the American Medical Association, vol. 292, no. 23, pp. 2839–2848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  151. R. T. Chung, J. Andersen, P. Volberding et al., “Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons,” The New England Journal of Medicine, vol. 351, no. 5, pp. 451–459, 2004. View at Publisher · View at Google Scholar · View at Scopus
  152. M. Rodriguez-Torres, J. Slim, L. Bhatti et al., “Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial,” HIV Clinical Trials, vol. 13, no. 3, pp. 142–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  153. M. Sulkowski, S. Pol, J. Mallolas et al., “Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial,” The Lancet Infectious Diseases, vol. 13, no. 7, pp. 597–605, 2013. View at Publisher · View at Google Scholar · View at Scopus
  154. F. J. Torriani, M. Rodriguez-Torres, J. K. Rockstroh et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients,” The New England Journal of Medicine, vol. 351, no. 5, pp. 438–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. D. Dieterich, M. Nelson, V. Soriano et al., “Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV,” AIDS, vol. 29, no. 5, pp. 571–581, 2015. View at Publisher · View at Google Scholar · View at Scopus
  156. D. Dieterich, J. K. Rockstroh, C. Orkin et al., “Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV Genotype 1 and HIV-1: A phase 3 study,” Clinical Infectious Diseases, vol. 59, no. 11, pp. 1579–1587, 2014. View at Publisher · View at Google Scholar · View at Scopus
  157. M. S. Sulkowski, K. E. Sherman, D. T. Dieterich et al., “Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial,” Annals of Internal Medicine, vol. 159, no. 2, pp. 86–96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  158. M. Rodriguez-Torres, A. Gaggar, G. Shen et al., “Sofosbuvir for chronic hepatitis C virus infection genotype 1–4 in patients coinfected with HIV,” Journal of Acquired Immune Deficiency Syndromes, vol. 68, no. 5, pp. 543–549, 2015. View at Publisher · View at Google Scholar · View at Scopus
  159. A. Osinusi, E. G. Meissner, Y.-J. Lee et al., “Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics a randomized clinical trial,” JAMA, vol. 310, no. 8, pp. 804–811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Zeuzem, G. M. Dusheiko, R. Salupere et al., “Sofosbuvir and Ribavirin in HCV genotypes 2 and 3,” The New England Journal of Medicine, vol. 370, no. 21, pp. 1993–2001, 2014. View at Publisher · View at Google Scholar · View at Scopus
  161. P. J. Ruane, D. Ain, R. Stryker et al., “Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry,” Journal of Hepatology, vol. 62, no. 5, pp. 1040–1046, 2015. View at Publisher · View at Google Scholar · View at Scopus
  162. N. Afdhal, K. R. Reddy, D. R. Nelson et al., “Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection,” The New England Journal of Medicine, vol. 370, no. 16, pp. 1483–1493, 2014. View at Publisher · View at Google Scholar · View at Scopus
  163. N. Afdhal, S. Zeuzem, P. Kwo et al., “Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection,” The New England Journal of Medicine, vol. 370, no. 20, pp. 1889–1898, 2014. View at Publisher · View at Google Scholar · View at Scopus
  164. K. V. Kowdley, S. C. Gordon, K. R. Reddy et al., “Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis,” The New England Journal of Medicine, vol. 370, no. 20, pp. 1879–1888, 2014. View at Publisher · View at Google Scholar · View at Scopus
  165. Z. M. Younossi, M. Stepanova, P. Marcellin et al., “Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials,” Hepatology, vol. 61, no. 6, pp. 1798–1808, 2015. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Naggie, C. Cooper, M. S. Saag et al., “Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections, Abstract 152LB, Seattle, Wash, USA, February 2015.
  167. M. P. Curry, R. Bacon, D. Dieterich et al., “Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: real-world experience from the TRIO network,” in Proceedings of the 66th Annual Meeting of the American Association for the Study of Liver Diseases, p. 755, San Francisco, Calif, USA, November 2015.
  168. K. R. Reddy, M. Bourlière, M. Sulkowski et al., “Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis,” Hepatology, vol. 62, no. 1, pp. 79–86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  169. P. Andreone, M. G. Colombo, J. V. Enejosa et al., “ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection,” Gastroenterology, vol. 147, no. 2, pp. 359–3650.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  170. J. J. Feld, K. V. Kowdley, E. Coakley et al., “Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin,” The New England Journal of Medicine, vol. 370, no. 17, pp. 1594–1603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  171. P. Ferenci, D. Bernstein, J. Lalezari et al., “ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV,” The New England Journal of Medicine, vol. 370, no. 21, pp. 1983–1992, 2014. View at Publisher · View at Google Scholar · View at Scopus
  172. F. Poordad, C. Hezode, R. Trinh et al., “ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis,” The New England Journal of Medicine, vol. 370, no. 21, pp. 1973–1982, 2014. View at Publisher · View at Google Scholar · View at Scopus
  173. S. Zeuzem, I. M. Jacobson, T. Baykal et al., “Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin,” The New England Journal of Medicine, vol. 370, no. 17, pp. 1604–1614, 2014. View at Publisher · View at Google Scholar · View at Scopus
  174. M. S. Sulkowski, O. J. Eron, D. Wyles et al., “Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial,” The Journal of the American Medical Association, vol. 313, no. 12, pp. 1223–1231, 2015. View at Publisher · View at Google Scholar · View at Scopus
  175. Abb Vie Corporation, HOLKIRA PAK Product Monograph, 2015, http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/HOLKIRA_PAK_PM_EN.pdf.
  176. E. Lawitz, M. S. Sulkowski, R. Ghalib et al., “Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study,” The Lancet, vol. 384, no. 9956, pp. 1756–1765, 2014. View at Publisher · View at Google Scholar · View at Scopus
  177. P. Kwo, N. Gitlin, R. Nahass et al., “Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study,” Hepatology, 2016. View at Publisher · View at Google Scholar
  178. E. Lawitz, G. Matusow, E. DeJesus et al., “LP04: a phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2,” Journal of Hepatology, vol. 62, supplement 2, pp. S264–S265, 50th Annual Meeting of the European Association for the Study of the Liver (EASL)—The International Liver Congress; April 22–25; Vienna, Austria, 2015. View at Publisher · View at Google Scholar
  179. M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-Torres et al., “Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection,” The New England Journal of Medicine, vol. 370, no. 3, pp. 211–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  180. D. L. Wyles, P. J. Ruane, M. S. Sulkowski et al., “Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1,” The New England Journal of Medicine, vol. 373, no. 8, pp. 714–725, 2015. View at Publisher · View at Google Scholar · View at Scopus
  181. J. K. Rockstroh, M. Nelson, C. Katlama et al., “Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial,” The Lancet HIV, vol. 2, no. 8, pp. e319–e327, 2015. View at Publisher · View at Google Scholar
  182. E. Lawitz, A. Mangia, D. Wyles et al., “Sofosbuvir for previously untreated chronic hepatitis C infection,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1878–1887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  183. I. M. Jacobson, S. C. Gordon, K. V. Kowdley et al., “Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1867–1877, 2013. View at Publisher · View at Google Scholar · View at Scopus
  184. E. Lawitz, F. Poordad, D. M. Brainard et al., “Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis,” Hepatology, vol. 61, no. 3, pp. 769–775, 2015. View at Publisher · View at Google Scholar · View at Scopus
  185. G. R. Foster, S. Pianko, C. Cooper et al., “LO5 : sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the boson study,” Journal of Hepatology, vol. 62, pp. S259–S260, 2015, (Proceedings of th 50th Annual Meeting of the European Association for the Study of the Liver (EASL)—The International Liver Congress; April 22–26; Vienna, Austria). View at Publisher · View at Google Scholar
  186. V. Leroy, P. Angus, J. P. Bronowicki et al., “All-oral treatment with Daclatasvir (DCV) Plus Sofosbuvir (SOF) Plus Ribavirin (RBV) for 12 or 16 weeks in HCV Genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study [abstract LB-3],” Hepatology, p. 1380A-1A, Program and Abstracts of the Liver Meeting—2015—American Association for the Study of Liver Diseases; November 13–17; San Francisco, CA, 2015.
  187. M. S. Sulkowski, S. Naggie, J. Lalezari et al., “Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection,” The Journal of the American Medical Association, vol. 312, no. 4, pp. 353–361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  188. J.-M. Molina, C. Orkin, D. M. Iser et al., “Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study,” The Lancet, vol. 385, no. 9973, pp. 1098–1106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  189. E. Gane, R. H. Hyland, A. Di et al., “Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 study,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases, abstract LB-11, p. 236A, Boston, Mass, USA, November 2014.
  190. C. Hézode, T. Asselah, K. R. Reddy et al., “Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial,” The Lancet, vol. 385, no. 9986, pp. 2502–2509, 2015. View at Publisher · View at Google Scholar · View at Scopus
  191. A. Kohli, R. Kapoor, Z. Sims et al., “Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study,” The Lancet Infectious Diseases, vol. 15, no. 9, pp. 1049–1054, 2015. View at Publisher · View at Google Scholar · View at Scopus
  192. K. L. Berger, J. Scherer, M. Ranga et al., “Baseline polymorphisms and emergence of drug resistance in the NS3/4A protease of HCV genotype-1 following treatment with faldaprevir plus pegylated interferon alfa-2a and ribavirin in phase 2 and phase 3 studies,” Antimicrobial Agents and Chemotherapy, 2015. View at Publisher · View at Google Scholar
  193. F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for untreated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  194. I. M. Jacobson, G. J. Dore, G. R. Foster et al., “Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 384, no. 9941, pp. 403–413, 2014. View at Publisher · View at Google Scholar · View at Scopus
  195. I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al., “Telaprevir for previously untreated chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2405–2416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  196. J. C. Sullivan, S. De Meyer, D. J. Bartels et al., “Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials,” Clinical Infectious Diseases, vol. 57, no. 2, pp. 221–229, 2013. View at Publisher · View at Google Scholar · View at Scopus
  197. K. Bichoupan, N. Tandon, R. Yalamanchili et al., “Real-world pharmaceutical costs in the simeprevir/sofosbuvir era: $164,485 per SVR4,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI '15), abstract 149, p. 17, International Antiviral Society, Seattle, Wash, USA, February 2015.
  198. D. Wyles, P. Pockros, G. Morelli et al., “Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens,” Hepatology, vol. 61, no. 6, pp. 1793–1797, 2015. View at Publisher · View at Google Scholar · View at Scopus
  199. C. Sarrazin, H. Dvory-Sobol, E. Svarovskaia, B. Doehle, and J. McCarville, “Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir ± RBV,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD '14), abstract 1926, Boston, Mass, USA, November 2014.
  200. “Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir,” in Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver, H. Dvory-Sobol, D. Wyles, W. Ouyang et al., Eds., Journal of Hepatology, Vienna, Austria, April 2015.
  201. E. Lawitz, S. Flamm, J. C. Yang et al., “O005: Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks,” Journal of Hepatology, vol. 62, supplement 2, p. S192, 50th Annual Meeting of the European Association for the study of the Liver (EASL)—The International Liver Congress; April 22–26; Vienna, Austria, 2015.
  202. S. A. Alqahtani, N. Afdhal, S. Zeuzem et al., “afety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials,” Hepatology, vol. 62, no. 1, pp. 25–30, 2015. View at Publisher · View at Google Scholar · View at Scopus
  203. S. Naggie, C. Cooper, M. Saag et al., “Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1,” The New England Journal of Medicine, vol. 373, no. 8, pp. 705–713, 2015. View at Publisher · View at Google Scholar · View at Scopus
  204. P. Krishnan, R. Tripathi, G. Schnell et al., “Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir-based regimens [0057],” Journal of Hepatology, p. S220, 50th Annual Meeting of the European Association for the Study of the Liver; April 22–26; Vienna, Austria, 2015.
  205. J. J. Kiser, J. R. Burton, P. L. Anderson, and G. T. Everson, “Review and management of drug interactions with boceprevir and telaprevir,” Hepatology, vol. 55, no. 5, pp. 1620–1628, 2012. View at Publisher · View at Google Scholar · View at Scopus
  206. A. Tseng and M. Foisy, “Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and Non-HIV drugs,” Current Infectious Disease Reports, vol. 14, no. 1, pp. 67–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  207. D. E. Vance, M. Mugavero, J. Willig, J. L. Raper, and M. S. Saag, “Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life,” Journal of the Association of Nurses in AIDS Care, vol. 22, no. 1, pp. 17–25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  208. C. de Kanter, M. Blonk, A. Colbers, Q. Fillekes, B. Schouwenberg, and D. Burger, “The influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase Inhibitor raltegravir,” in Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections, abstract 772LB, Seattle, Wash, USA, March 2012.
  209. A. Moreno, C. Quereda, M. Montes et al., “Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir,” Journal of Acquired Immune Deficiency Syndromes, vol. 61, no. 3, pp. e47–e49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  210. J. J. Eron, B. Young, D. A. Cooper et al., “Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials,” The Lancet, vol. 375, no. 9712, pp. 396–407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  211. K. E. Hightower, R. Wang, F. DeAnda et al., “Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 10, pp. 4552–4559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  212. L. Caro, J. E. Talaty, Z. Guo et al., “Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted hiv protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers,” in Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD '13), abstract 487, Washington, DC, USA, November 2013.
  213. J. E. Talaty, L. Caro, W. Yeh et al., “Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and efavirenz in normal healthy volunteers,” in Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD '13), abstract 492, Washington, DC, USA, November 2013.
  214. W. Yeh, W. Marshall, J. Ma et al., “Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI '14), abstract 638, Boston, Mass, USA, March 2014.
  215. “Pharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI '14), W. Yeh, W. Marshall, E. Mangin et al., Eds., abstract 498, Boston, Mass, USA, March 2014.
  216. W. Yeh, H. Feng, P. Auger et al., “No pharmacokinetic interaction between HCV inhibitors grazoprevir/elbasvir with rilpivirine,” in Proceedings of the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, abstract 63, Washington, DC, USA, May 2015.
  217. W. Yeh, I. P. Fraser, L. Caro et al., “No meaningful PK interaction between HCV protease inhibitor MK-5172 and tenofovir or raltegravir,” in Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections (CROI '14), abstract 500, Boston, Mass, USA, March 2014.
  218. W. Yeh, T. Marenco, H. P. Feng et al., “Drug-drug interaction between HCV inhibitors grazoprevir/elbasvir with dolutegravir,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI '15), abstract 522, Seattle, Wash, USA, February 2015.
  219. L. Caro, W. Marshall, H. Feng et al., “Coadministration of HCV protease inhibitor grazoprevir with HCV NS5A inhibitor elbasvir has no effect on pravastatin but increases rosuvastatin exposure in healthy subjects,” in Proceedings of the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, DC, USA, May 2015.
  220. C. Marzolini, L. Elzi, S. Gibbons et al., “Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV cohort study,” Antiviral Therapy, vol. 15, no. 3, pp. 413–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  221. R. Cope, T. Glowa, S. Faulds, P. Veldkamp, R. Prasad, and A. Pickering, “Majority of HIV/HCV patients need to switch ART to accommodate simeprevir,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI '15), abstract 651, Seattle, Wash, USA, February 2015.
  222. R. G. Tirona and D. G. Bailey, “Herbal product-drug interactions mediated by induction,” British Journal of Clinical Pharmacology, vol. 61, no. 6, pp. 677–681, 2006. View at Publisher · View at Google Scholar · View at Scopus
  223. R. Klein, K. Struble, and S. Morin, FDA Hepatitis Update—Important Safety Information: Harvoni, and Sovaldi, US Food and Drug Administration, Silver Spring, Md, USA, 2015, http://content.govdelivery.com/accounts/USFDA/bulletins/f97c71.
  224. J. Lalezari, J. Sullivan, V. Rustgi et al., “Abbvie IFN-free 3 DAA regimen in HCV genotype 1-infected patients on methadone or buprenorphine,” in Proceedings of the 21st Annual Conference on Retroviruses and Opportunistic Infections, Boston, Mass, USA, March 2014.
  225. S. Ouwerkerk-Mahadevan, M. Beaumont-Mauviel, M. Peeters et al., “The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone,” in Proceedings of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD '12), abstract 1353, Boston, Mass, USA, November 2012.
  226. R. Menon, P. Badri, U. Das et al., “Drug-drug interactions with direct acting antiviral combination therapy of ABT-450/r, ombitasvir and dasabuvir,” in Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '14), abstract A-007, Washington, DC, USA, September 2014.
  227. K. Garrison, J. Custodio, P. S. Pang et al., “Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens,” in Proceedings of the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, DC, USA, May 2015.
  228. A. Khatri, R. Trinh, W. Zhao, T. Podsadecki, and R. Menon, “Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine,” in Proceedings of the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, DC, USA, May 2015.
  229. I. Song, F. Jerva, J. Zong et al., “Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects,” in Proceedings of the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, DC, USA, May 2015.
  230. Janssen Inc, Galexos (Simeprevir) Product Monograph, Janssen Inc, Toronto, Canada, 2013.
  231. “Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus NS3/4A protease inhibitor. (Abstract PE 10/7),” in Proceedings of the Program and Abstracts of the 14th European AIDS Conference (EACS '13), S. Ouwerkerk-Mahadevan, A. Simion, M. Peeters, and M. Beumont-Mauviel, Eds., Brussels, Belgium, October 2013.
  232. “No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers,” in Proceedings of the Program and Abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD '12), B. Kirby, A. Mathias, S. Rossi, C. Moyer, G. Shen, and B. P. Kearney, Eds., abstract 1877, Boston, Mass, USA, November 2012.
  233. “The pharmokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers,” in Proceedings of the Program and Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections, S. Ouwerkerk-Mahadevan, V. Sekar, M. Peeters, and M. Beumont-Mauviel, Eds., abstract 49, Seattle, Wash, USA, March 2012.
  234. T. Eley, X. You, R. Wang et al., Daclatasvir: Overview of Drug-Drug Interactions with Antretroviral Agents and Other Common Comcomitant Drugs, HIV DART, Miami, Fla, USA, 2014.
  235. C. Boesecke and J. K. Rockstroh, “Treatment of acute hepatitis C infection in HIV-infected patients,” Current Opinion in HIV and AIDS, vol. 6, no. 4, pp. 278–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  236. F. Marcellin, B. Demoulin, M. Suzan-Monti et al., “Risk factors for HCV reinfection or transmission in HIV-HCV coinfected MSM (ANRS-VESPA2 French National Survey),” Journal of Acquired Immune Deficiency Syndromes, vol. 70, no. 5, pp. e179–e182, 2015. View at Publisher · View at Google Scholar
  237. J. Wong, D. Moore, S. Kanters et al., “Seroprevalence of hepatitis C and correlates of seropositivity among men who have sex with men in Vancouver, Canada: a cross-sectional survey,” Sexually Transmitted Infections, vol. 91, no. 6, pp. 430–433, 2015. View at Publisher · View at Google Scholar · View at Scopus
  238. G. V. Matthews, M. Hellard, P. Haber et al., “Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C,” Clinical Infectious Diseases, vol. 48, no. 5, pp. 650–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  239. H. Nomura, S. Sou, H. Tanimoto et al., “Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial,” Hepatology, vol. 39, no. 5, pp. 1213–1219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  240. E. Kenny-Walsh, “Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group,” The New England Journal of Medicine, vol. 340, no. 16, pp. 1228–1233, 1999. View at Publisher · View at Google Scholar
  241. M. R. Prasad and J. R. Honegger, “Hepatitis C virus in pregnancy,” American Journal of Perinatology, vol. 30, no. 2, pp. 149–159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  242. T. Jabeen, B. Cannon, J. Hogan et al., “Pregnancy and pregnancy outcome in hepatitis C type 1b,” QJM, vol. 93, no. 9, pp. 597–601, 2000. View at Google Scholar
  243. E. A. Roberts and L. Yeung, “Maternal-infant transmission of hepatitis C virus infection,” Hepatology, vol. 36, no. 5, supplement 1, pp. S106–S113, 2002. View at Publisher · View at Google Scholar · View at Scopus
  244. E. E. Mast, L.-Y. Hwang, D. S. Y. Seto et al., “Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy,” Journal of Infectious Diseases, vol. 192, no. 11, pp. 1880–1889, 2005. View at Publisher · View at Google Scholar · View at Scopus
  245. E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi, “Global epidemiology and genotype distribution of the hepatitis C virus infection,” Journal of Hepatology, vol. 61, supplement, no. 1, pp. S45–S57, 2014. View at Publisher · View at Google Scholar · View at Scopus
  246. F. M. Shebl, S. S. El-Kamary, D. A. Saleh et al., “Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages,” Journal of Medical Virology, vol. 81, no. 6, pp. 1024–1031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  247. S. Castellino, S. Lensing, C. Riely et al., “The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort,” Blood, vol. 103, no. 7, pp. 2460–2466, 2004. View at Publisher · View at Google Scholar · View at Scopus
  248. L. Pickering, C. Baker, D. Kimberlin, and S. Long, “Red Book: 2009 report of the committee on infectious diseases,” in Red Book, L. Pickering, Ed., pp. 357–360, American Academy of Pediatrics, Elk Grove Village, Ill, USA, 2009. View at Google Scholar
  249. P. Jara, L. Hierro, A. de la Vega et al., “Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children with chronic hepatitis C infection,” Pediatric Infectious Disease Journal, vol. 27, no. 2, pp. 142–148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  250. K. B. Schwarz, P. Mohan, M. R. Narkewicz et al., “Safety, efficacy and pharmacokinetics of peginterferon α2a (40 kd) in children with chronic hepatitis C,” Journal of Pediatric Gastroenterology and Nutrition, vol. 43, no. 4, pp. 499–505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  251. E. Druyts, K. Thorlund, P. Wu et al., “Efficacy and safety of pegylated interferon Alfa-2a or Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis,” Clinical Infectious Diseases, vol. 56, no. 7, pp. 961–967, 2013. View at Publisher · View at Google Scholar · View at Scopus
  252. C. L. Cooper, “Managing the side effects of therapy,” in Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future, M. L. Shiffman, Ed., pp. 171–182, Springer, New York, NY, USA, 2012. View at Publisher · View at Google Scholar
  253. S. Rodríguez-Nóvoa, J. Morello, M. González et al., “Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin,” AIDS, vol. 22, no. 18, pp. 2535–2537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  254. D. Zhang, T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. Griffith Humphreys, “In vitro inhibition of udp glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation,” Drug Metabolism and Disposition, vol. 33, no. 11, pp. 1729–1739, 2005. View at Publisher · View at Google Scholar · View at Scopus
  255. J. M. Miro, P. Stock, E. Teicher, J.-C. Duclos-Vallée, N. Terrault, and A. Rimola, “Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update,” Journal of Hepatology, vol. 62, no. 3, pp. 701–711, 2015. View at Publisher · View at Google Scholar · View at Scopus
  256. J. O'Grady, C. Taylor, and M. G. Brook, “Guidelines for liver transplantation in patients with HIV infection (2005),” HIV Medicine, vol. 6, supplement 2, pp. 149–153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  257. P. G. Stock and M. E. Roland, “Evolving clinical strategies for transplantation in the HIV-positive recipient,” Transplantation, vol. 84, no. 5, pp. 563–571, 2007. View at Publisher · View at Google Scholar · View at Scopus
  258. C. Cooper, S. Kanters, M. Klein et al., “Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort,” AIDS, vol. 25, no. 6, pp. 777–786, 2011. View at Publisher · View at Google Scholar · View at Scopus
  259. J. M. Miró, F. Agüero, M. Laguno et al., “Liver transplantation in HIV/hepatitis co-infection,” Journal of HIV Therapy, vol. 12, no. 1, pp. 24–35, 2007. View at Google Scholar · View at Scopus
  260. Y. Sugawara, S. Tamura, and N. Kokudo, “Liver transplantation in HCV/HIV positive patients,” World Journal of Gastrointestinal Surgery, vol. 3, no. 2, pp. 21–28, 2011. View at Google Scholar
  261. E. Anadol, S. Beckebaum, K. Radecke et al., “Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany,” AIDS Research and Treatment, vol. 2012, Article ID 197501, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  262. J. M. Miro, M. Montejo, L. Castells et al., “Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study,” American Journal of Transplantation, vol. 12, no. 7, pp. 1866–1876, 2012. View at Publisher · View at Google Scholar · View at Scopus
  263. I. Campos-Varela, M. G. Peters, and N. A. Terrault, “Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting,” Clinical Infectious Diseases, vol. 60, no. 1, pp. 108–116, 2014. View at Publisher · View at Google Scholar
  264. D. Samuel, M. Charlton, E. Gane et al., “Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study,” in Proceedings of the 49th Annual Meeting of the European Association for the Study of the Liver, Abstracts of the International Liver Congress™, p. S499, London, UK, April 2014.
  265. K. R. Reddy, G. Everson, S. Flamm et al., “Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study [oral presentation #8],” Hepatology, p. 49A, 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2014; November 9; Boston, MA, 2014.
  266. K. J. Wilby, E. D. Greanya, J.-A. E. Ford, E. M. Yoshida, and N. Partovi, “A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients,” Annals of Hepatology, vol. 11, no. 2, pp. 179–185, 2012. View at Google Scholar · View at Scopus
  267. V. Garg, R. P. G. Van Heeswijk, J. E. Lee, K. Alves, P. Nadkarni, and X. Luo, “Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus,” Hepatology, vol. 54, no. 1, pp. 20–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  268. “Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and the calcineurin inhibitors cyclosporine and tacrolimus,” in Proceedings of the Program and Abstracts of HEP DART, E. Hulskotte, S. Gupta, F. Xuan et al., Eds., abstract 123, Koloa, Hawaii, USA, December 2011.
  269. N. Terrault, K. R. Reddy, F. Poordad et al., “Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients,” American Journal of Transplantation, vol. 14, no. 5, pp. 1129–1135, 2014. View at Publisher · View at Google Scholar · View at Scopus
  270. M. Charlton, “Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail,” Hepatology, vol. 54, no. 1, pp. 3–5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  271. V. Saxena and N. Terrault, “Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies,” Current Opinion in Organ Transplantation, vol. 17, no. 3, pp. 216–224, 2012. View at Publisher · View at Google Scholar · View at Scopus